非小细胞肺癌预后影响因素与靶向治疗药的疗效评估  

The Prognosis Factors of Non-small Cell Lung Cancer and Curative Effect Evaluation of Targeted Therapy Drug

作　　者：陈耐华 

机构地区：[1]辽宁省锦州市太和区医院,辽宁锦州121000

出　　处：《中国医学创新》2016年第1期21-24,共4页Medical Innovation of China

摘　　要：目的:分析非小细胞肺癌患者预后的因素及应用靶向治疗药物的疗效评估。方法:回顾性分析非小细胞肺癌患者65例,给予靶向治疗药吉非替尼,随访并分析性别、年龄、病理类型、吸烟、淋巴结、肿块的大小变化对肺癌预后的影响。疗效评估RECIST1.1标准分为CR(完全缓解)、PR(部分缓解)、PD(疾病进展)、SD(病灶稳定);将SD分为两组,A组为目标病灶最大径减少小于30%,B组为目标病灶最大径增加不足20%。采用Kaplan-Meier法进行生存分析,Log-rank检验比较中位生存期有无差异,采用Cox比例风险模型进行多因素生存分析。结果:吸烟、淋巴结影响患者的生存期(P<0.05);吸烟、肿块大小变化是患者预后的独立因素(P<0.05)。3例CR,15例PR,16例PD,31例SD,其中A组15例,B组16例。结论:吸烟、肿块大小变化是患者预后的主要因素,RECIST1.1标准是否应用于靶向治疗药物的疗效评估尚未确定。Objective： To analyze the prognosis factors of non-small cell lung cancer and curative effect evaluation of targeted therapy drug. Method： 65 patients with non-small cell lung cancer were given targeted therapy drug （ gefitinib ）, then followed-up and analyzed gender, age, pathological type, smoking, lymph nodes, the size of the mass change on the influence of the prognosis of lung cancer. RECISTI.1 curative effect evaluation standard was divided into complete response （ CR ）, partial response （ PR ）, progressive disease （ PD ）, stable disease （ SD ）, and SD was divided into two groups, group A was target lesion maximum diameter reduced less than 30%, group B was target lesion maximum diameter increased less than 20%. The Kaplan-Meier method for survival analysis, Log-rank tested comparison between median survival difference, adopted the Cox proportional risk model for multiple factors survival analysis. Result： Smoking, lymph node affected the person＇s life cycle （ P〈0.05 ） . Smoking and tumor size changing was independent factors prognosis of patients. 3 cases showed CR, 15 cases PR, 16 cases PD, 31 cases SD that contained 15 cases in the group A, and 16 cases in the group B. Conclusion： Smoking and tumor size changing are independent factors for prognosis, RECISTI.1 standard is applied to evaluate the therapeutic efficacy of drugs targeted therapy has not been established.

关 键 词：非小细胞肺癌 预后 疗效评价 RECIST标准 靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]